Efficacy of fractional erbium laser-assisted tranexamic acid delivery in facial melasma

Phase 4

Completed

• Conditions: Facial melasma; Facial; Melasma; Tranexamic acid; Fractional ErbiumYAG; Laser

• Registration Number: TCTR20210302002
• Lead Sponsor: Sasima Eimpunth, MD

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2020-04-30
• Study Start: 2021-03-02
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

1.Age more than 18 years old with diagnosis of melasma by board-certified dermatologist
2. Not receive any topical melasma medications within 1 month before the participation
3. Not receive any laser treatments for melasma within 3 months before the participation
4. Can follow the study protocol

Exclusion Criteria

1. Receive any topical melasma medications within 1 month before the participation
2. Receive any laser treatments for melasma within 3 months before the participation
3. Receive any birth control pills or hormonal injections for birth control
4. Receive any estrogen or progesterone treatment
5. History of allergy or any side effects related to tranexamic acid
6. Any skin inflammation or sunburn on the face
7. Any skin infection on the face
8. Pregnancy or lactating woman
9. History of keloids
10. History of heart diseases, valvular heart diseases, or abnormal blood coagulation; for example; deep vein thrombosis, angina, or stroke

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of melasma baseline, week2, 4,8,12,16,20,32 Melasma Area and Severity Index (MASI) score,Mexameter baseline, wk2,4,8,12,16,20,32 Mexameter,Photo evaluation baseline, week2,4,8,12,16,20,32 Clinical photography,Patient evaluation week4,8,12,16,20,32 Visual analog scale

Secondary Outcome Measures

Name	Time	Method
Adverse effects baseline, wk2,4,8,12,16,20,32 Clinical